$SBUX expects FY16 GAAP EPS to be in the range of $1.85-1.86. Non-GAAP EPS is now expected to be $1.88 to $1.89. Full year 2016 consolidated revenue growth is expected to be 10% plus on a 52-week basis and the 53rd week is expected to add approx. 2%.
$XLNX said that it's too early to predict the revenue from $AMZN's partnership. The company said that it is unlikely to impact the next 18 months in a significant way. By 2020, if this goes well, the market could be larger, $XLNX said.
In terms of $VZ deal, $EQIX said the customer responds to the pending acquisition is very positive and it is very optimistic about the quality of assets its getting from the deal. The company is in process of acquiring 29 data centers from Verizon in the U.S. and Latin America for $3.6Bil.
$TSCO is pleased with the performance of Petsense. The company
will look into expansion opportunities during 2017. $TSCO believes Petsense has
tremendous store count as well as online and dial and pick-up in-store
$AMGN believes that its cholesterol lowering drug Repatha to be an important product in the cardiovascular area. In 1Q17, the company achieved positive results for XGEVA drug. Subject to regulatory approvals, $AMGN looks forward to offer this therapy to multiple myeloma patients, many of whom are at risk of skeletal-related events.